Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4846410 | 0.84 | CYP3A4 (0.33) | CYP3A4TDP1DRD1 | |
| SCHEMBL4842061 | 0.84 | CYP3A4 (0.33) | CYP3A4TDP1DRD1 | |
| SCHEMBL4906697 | 0.76 | AKR1B1 (0.30) | DRD1 | |
| SCHEMBL4837678 | 0.72 | DRD1 (0.38) | CYP3A4TDP1DRD1 | |
| SCHEMBL12880853 | 0.69 | CYP3A4 (0.41) | CYP3A4TDP1DRD1 | |
| SCHEMBL6668999 | 0.69 | ESR1 (0.42) | CYP3A4TDP1DRD1 | |
| SCHEMBL29352284 | 0.69 | ABCG2 (0.39) | CYP3A4TDP1DRD1 | |
| SCHEMBL27899 | 0.69 | ABCG2 (0.39) | CYP3A4TDP1DRD1 | |
| SCHEMBL29365010 | 0.69 | ITGB2 (0.39) | CYP3A4TDP1DRD1 | |
| SCHEMBL2076685 | 0.69 | ABCG2 (0.39) | CYP3A4TDP1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636243-B1 | CHIRAL LIGANDS FOR APPLICATION IN ASYMMETRIC SYNTHESES | BOEHRINGER INGELHEIM INT (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-7396947-B2 | Chiral ligands for application in asymmetric syntheses | LANXESS DEUTSCHLAND GMBH (DE) | 2008-07-08 | — | — | US | disclosed |
| US-20070004927-A1 | Chiral ligands for application in asymmetric syntheses | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20060161022-A1 | Chiral ligands for application in asymmetric syntheses | LANXESS DEUTSCHLAND GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| EP-1636243-A2 | CHIRAL LIGANDS FOR APPLICATION IN ASYMMETRIC SYNTHESES | LANXESS Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111063-A2 | CHIRAL LIGANDS FOR APPLICATION IN ASYMMETRIC SYNTHESES | LANXESS DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004927-A1 | Chiral ligands for application in asymmetric syntheses | COASY, SPR, DHPS | CYP3A4 161/4885TDP1 3362/4885DRD1 1536/4885 |
| US-20060161022-A1 | Chiral ligands for application in asymmetric syntheses | COASY, SPR, DHPS | CYP3A4 161/4885TDP1 3362/4885DRD1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.